The science of improved absorption

Seracal is the only dietary solution clinically proven to increase fat and nutrient absorption from food1-3

Colorful structure of Seracal product

Rooted in science, backed by results

When patients struggle to absorb fat and nutrients from the foods they eat, Seracal works with the body’s natural digestion process to provide highly absorbable fat calories, essential fatty acids, choline, and vitamins A and E to food.1,4

Seracal helps the body better absorb fat and fat-soluble nutrients contained in the food being eaten while being a healthy source of calories itself (70 kcal/serving).

Seracal:

Liquid drop icon

Improves fat and nutrient absorption

Scales icon

Encourages healthy weight gain

Stomach icon

Reduces uncomfortable gastrointestinal (GI) symptoms, like bloating, cramps, and diarrhea

The research behind Seracal speaks for itself. With strong clinical evidence, Seracal’s effectiveness is clear, supported by data, and proven in practice.

A $7M NIH-funded study compared Lym-X-Sorb®, the active technology in Seracal, to standard fats over 12 months using the same primary endpoint as a leading biotech product.1

The study found that Lym-X-Sorb improved:

Liquid drop icon

Absorption of fats

3 drops and arrows down icon

Absorption of other fats and nutrients in the meal

Chemical bond icon

Choline to near-healthy levels

Fat absorption: All study subjects (n=110)1†

graph that displays the Coefficient of fat absorption (CFA). There is a -1.4-point change in 3 months with Active Control and a 7.5-point change with Seracal
graph that displays the Coefficient of fat absorption (CFA). There is a 1-point change in 3 months with Active Control and a 6-point change with Seracal

Fat absorption: Moderate-to-low baseline CFA group (baseline CFA <88%, n=66)2‡

graph that displays the Coefficient of fat absorption (CFA). There is a 1-point change in 3 months with Active Control and a 6-point change with Seracal
graph that displays the Coefficient of fat absorption (CFA). There is a -1.4-point change in 3 months with Active Control and a 7.5-point change with Seracal

p<0.05 (difference from baseline within randomization group)

All Subjects: n = 41 and 36 for the control group, and n = 35 and 27 for the Vytala group at baseline and 3 months respectively

Higher-Need Subjects: n=12 and 14 for the control group and Vytala group respectively

Patients with the lowest BMI and the highest need for weight gain saw the largest improvements.1
man smiling and holding the spoon in one hand and the orange jar in the other

In patients with impaired absorption and/or exocrine pancreatic insufficiency (EPI), food can’t be broken down to be absorbed and moves through the intestines, causing symptoms like gas, bloating, nausea, diarrhea, and weight loss.

By tracking the coefficient of fat absorption (CFA), clinicians can assess the efficacy of treatments like Seracal in improving fat absorption and managing conditions related to malabsorption.

Lym-X-Sorb use resulted in an increase of:

CFA by a mean of 6% over 12 months

stopwatch and plus icon
Mean CFA by 8% over 3 months among patients most at risk
increasing indicators on the graph
Weight, height, and BMI for patients with a greater need 3,5,6

Change in height, weight, and BMI at 3 months1 (subjects with moderate-to-low baseline CFA [<88%], n=26)

The bar chart compares three metrics—Height (HAZ), Weight (WAZ), and BMI (BMIZ)—between two groups: “Active Control” and “Seracal.” Each metric shows two bars, with “Active Control” in gray and “Seracal” in pink. • For Height (HAZ), “Active Control” has a value of 0.02, while “Seracal” has a higher value of 0.06. • For Weight (WAZ), “Active Control” is at 0.12, whereas “Seracal” is at 0.17. • For BMI (BMIZ), “Active Control” has a value of 0.14, with “Seracal” showing the highest value at 0.20. The pink bars for “Seracal” feature a bubble pattern, distinguishing them further from the solid gray bars representing “Active Control.”
The bar chart compares three metrics—Height (HAZ), Weight (WAZ), and BMI (BMIZ)—between two groups: “Active Control” and “Seracal.” Each metric shows two bars, with “Active Control” in gray and “Seracal” in pink. • For Height (HAZ), “Active Control” has a value of 0.02, while “Seracal” has a higher value of 0.06. • For Weight (WAZ), “Active Control” is at 0.12, whereas “Seracal” is at 0.17. • For BMI (BMIZ), “Active Control” has a value of 0.14, with “Seracal” showing the highest value at 0.20. The pink bars for “Seracal” feature a bubble pattern, distinguishing them further from the solid gray bars representing “Active Control.”

Seracal doesn’t just improve fat absorption — it drives healthy growth and improved outcomes. The results also suggest sustained benefits over time.1

Seracal is a medical food intended for the dietary management of malabsorption. It is recommended for use under medical supervision in adults and children over one year of age.

Seracal logo with play icon
Seracal in action

See how Seracal and Lym-X-Sorb technology work at the cellular level.

Seracal in action

Medical food your patients will love

We make Seracal easy to use – and easy to enjoy.

boy smiling and shows thumbs up
Small and big bag of Seracal product

Patients simply mix Seracal powder into their favorite foods. Our ingredients are plant-based, gluten-free, and tasteless, earning the approval of patients of all ages, dietary needs, and food preferences.

leaf icon
grain spike icon
raised hand icon and word "taste" near it

More pockets, more power: How Lym-X-Sorb micelles work

Lym-X-Sorb, the backbone of Seracal, has been used since 1984. This proprietary technology has unique characteristics to boost dietary fat absorption. What sets it apart? It’s all about the micelles.

In normal digestion, micelles carry fats across the intestinal barrier.

Seracal micelles have extra pockets, carrying more fat and nutrients for improved absorption.

Seracal structure with 3 points 1. Lysophosphatidylcholines (LPCs) for matrix cohesion 2.Fatty acids including alpha-linolenic and linoleic acids 3. Monoglycerides to provide caloric density
Seracal structure with 3 points 1. Lysophosphatidylcholines (LPCs) for matrix cohesion 2.Fatty acids including alpha-linolenic and linoleic acids 3. Monoglycerides to provide caloric density

Power up patient
nutrition

A young girl smiling and giving a thumbs up, with the phrase "Power Up Patient Nutrition" near her
Small and big bag of Seracal product

Connect with us to make Seracal available to your patients.

Green arrow
Get started

Seracal is a medical food to be used under medical supervision and is covered by most commercial insurers and state Medicaid plans. Seracal is reimbursable as a medical food under HCPCs S9432.

Receive updates and the latest product information and nutritional happenings.

Sign up now
colorful bubbles, green spoon, and text in a circle: "Get the scoop!"

Discover the evidence

Green arrow

Craving more information?
Let the evidence speak for itself.

  1. Stallings VA, et al. Improved residual fat malabsorption and growth in children with cystic fibrosis treated with a novel oral structured lipid supplement: A randomized controlled trial. PloS One. 2020;15(5):e0232685.
  2. Lepage G, et al. Effect of an organized lipid matrix on lipid absorption and clinical outcomes in patients with cystic fibrosis. J Pediatr. 2002 Aug;141(2):178-85. doi: 10.1067/mpd.2002.124305.
  3. Bertolaso C, et al. Fat-soluble vitamins in cystic fibrosis and pancreatic insufficiency: efficacy of a nutrition intervention. J Pediatr Gastroenterol Nutr. 2014 Apr;58(4):443-8.
  4. Stallings VA, et al. Effect of oral lipid matrix supplement on fat absorption in cystic fibrosis: A randomized placebo-controlled trial. J Pediatr Gastroenterol Nutr. 2016 63(6):676-80.
  5. Schall JI, et al. Choline supplementation with a structured lipid in children with cystic fibrosis: a randomized placebo-controlled trial. J Pediatr Gastroenterol Nutr. 2016 Apr;62(4):618-26.
  6. Alshaikh B, et al. Choline supplementation alters some amino acid concentrations with no change in homocysteine in children with cystic fibrosis and pancreatic insufficiency. Nutr Res. 2016; 36(5):418-29.
Back to top
©2024 Vytala Inc. All rights reserved.
Vytala logo
©2024 Vytala Inc. All rights reserved.
Facebook icon
Instagram icon
Linkedin icon